Important Notice: Limited Web Access Dec 16 to 18, 2016

AIChE will undertake a routine upgrade of our digital infrastructure over the weekend of December 16-18, 2016. During this period access to certain areas of the website will be limited. Learn more about how access will be affected.

Mark Brader

Mark Brader

Principal Scientist
Biogen Idec

Dr. Brader is a Principal Scientist and formulation technology group leader in the Protein Pharmaceutical Development department at Biogen Idec.  His protein formulation experience spans the full breadth of pharmaceutical protein product development, from candidate selection to BLA filing.  He has held leadership roles supporting drug product development to submission readiness and rapid formulation strategies supporting early phase clinical evaluation.  Previous roles include senior technical positions in the Pharmaceutics Department at Novo Nordisk, Denmark and Biopharmaceutical R&D at Eli Lilly and Company, Indianapolis.  His research interests include the application of biophysical analysis techniques to better understand interrelationships between protein structure and pharmaceutical stability.

Dr. Brader received his Ph.D. in Inorganic Chemistry from Massey University, New Zealand and has held postdoctoral positions in the Department of Biochemistry at the University of California at Riverside and Department of Chemistry at Rutgers University, New Jersey.  He holds a graduate certificate from Purdue University in regulatory and quality compliance.